The safety and efficacy of adalimumab for patients with moderately to severely active ulcerative colitis ( UC ) has been reported up to week 52 from the placebo-controlled trials ULTRA ( Ulcerative Colitis Long-Term Remission and Maintenance with Adalimumab ) 1 and 2 .